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Abstract 
Background: Patients with idiopathic normal pressure hydrocephalus (iNPH) have reduced cerebrospinal fluid (CSF) 
concentrations of amyloid-β (Aβ) and α- and β-cleaved soluble forms of amyloid precursor protein (sAPPα and sAPPβ). 
The aims of this study were to examine if changes could also be seen in the CSF for secreted metabolites of APP-like 
protein 1 (APLP1) and to explore the prognostic value of amyloid-related CSF biomarkers, as well as markers of neu-
ronal injury and astroglial activation, as regards to clinical outcome after shunt surgery.
Methods: Twenty patients diagnosed with iNPH, 10 improved and 10 unchanged by shunt surgery, and 20 neuro-
logically healthy controls were included. All patients were examined clinically prior to surgery and at 6-month follow-
up after surgery using the iNPH scale. Lumbar puncture was performed pre-operatively. CSF samples were analyzed 
for neurofilament light (NFL), Aβ isoforms Aβ38, Aβ40 and Aβ42, sAPPα, sAPPβ, APLP1 β-derived peptides APL1β25, 
APL1β 27 and APL1β 28 and YKL40 by immunochemical methods.
Results: The concentrations of all soluble forms of APP, all Aβ isoforms and APL1β28 were lower, whilst APL1β25 and 
APL1β27 were higher in the CSF of iNPH patients compared to controls. There was no difference in biomarker concen-
trations between patients who improved after surgery and those who remained unchanged.
Conclusions: The reduced CSF concentrations of Aβ38, Aβ40, Aβ42, sAPPα and sAPPβ suggest that APP expres-
sion could be downregulated in iNPH. In contrast, APLP1 concentration in the CSF seems relatively unchanged. The 
increase of APL1β25 and APL1β27 in combination with a slight decreased APL1β28 could be caused by more avail-
able γ-secretase due to reduced availability of its primary substrate, APP. The data did not support the use of these 
markers as indicators of shunt responsiveness.
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Background
Idiopathic normal pressure hydrocephalus (iNPH) is 
a condition with gait and balance disturbances, cogni-
tive decline and urinary incontinence in combination 
with enlarged cerebral ventricles [1, 2]. Shunt treatment 
improves more than 80 % of the patients [3]. Without sur-
gery, the clinical course is progressive and a delay in treat-
ment means a loss of function that cannot be restored [4]. 
Being one of the few treatable neurodegenerative condi-
tions, an accurate diagnosis and identification of patients 
who will benefit from shunt surgery is essential. The use 
of CSF biomarkers for such purposes has been identified 
as one of the priorities for hydrocephalus research [5].
Patients with iNPH exhibit suppressed CSF concen-
trations of amyloid-β (Aβ) and the precursors soluble 
amyloid precursor protein α-, and β- (sAPPα, sAPPβ), in 
combination with elevated neurofilament light protein 
(NFL) [6–9]. Hypothetically, this is thought to be due 
to a downregulation of APP in the periventricular tissue 
possibly caused by changed amyloid metabolism and/or 
a reduced clearance of extracellular fluid into CSF lead-
ing to lowered concentrations of APP-derived proteins in 
CSF [6].
Amyloid-like protein 1 (APLP1)-derived peptides are 
processed by similar enzymatic pathways as APP and share 
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related structural domains and functions [10–12]. APLP1 is 
processed into short Aβ-like peptides (APL1β25, 1β27 and 
1β28) [13]. APLP1 is a substrate for the enzyme γ-secretase 
and the ratio of APLP1-derived APL1β28 to total APL1β 
is a surrogate marker for Aβ42 production in the cen-
tral nervous system [13, 14]. Recently, it was reported 
that γ-secretase was higher in brain biopsies from iNPH 
patients with amyloid plaques than in those without [15].
The aim of this study was to examine CSF concentra-
tions of APLP1-derived peptides in iNPH, especially if 
the APL1β28 form was increased, and to explore the 
prognostic value of amyloid-related CSF biomarkers. 
For this purpose, we analyzed the APP-derived peptides 
sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42, the APLP1derived 
peptides APL1β25, APL1β27 and APL1β28 in CSF in 20 
patients with iNPH (10 improved and 10 unchanged by 
shunt operation) and 20 neurologically healthy controls.
Methods
Study populations
Ten iNPH patients improved after shunt surgery and 10 
non-improved were retrospectively selected. All were 
diagnosed in accordance with the international guide-
lines [16]. The patients were selected from our local 
database at the hydrocephalus unit at Sahlgrenska Uni-
versity Hospital on the premises that full medical data 
pre- and postoperatively were available and that there 
was sufficient CSF stored to perform the analyses. In all, 
the database contained 176 patients. From the database, 
the 10 patients who benefitted the most from surgery (as 
defined by improvement in the iNPH scale) and fulfilled 
the inclusion criteria were selected. In the group that did 
not benefit from surgery, medical records were scanned 
in order to establish that at time for follow-up all shunts 
were working, none had complications and that that 
there be no other known cause for non-improvement. 
Patients who had complications that could be attributed 
to shunt surgery were excluded. In all, the groups were 
selected in order to magnify the difference in responsive-
ness to shunt surgery within the clinical material and 
analyze two clearly-distinguishable extreme groups as 
regards to shunt responsiveness.
The improved 10 patients consisted of five men and five 
women, aged 70.3 ± 3.20 (mean ± SD) and the 10 unim-
proved patients (<5 points at the iNPH scale) consisted of 
seven men and three women aged 71.6 ± 8 (mean ± SD). 
The groups did not differ significantly in terms of comor-
bidities, preoperative MMSE scores, extent of white 
matter lesions (WML), age or sickness duration. The 
baseline clinical data of the different groups are outlined 
in Table 1.
All patients were examined clinically prior to sur-
gery and 6  months after by the iNPH scale, composed 
of items assessing gait, cognition, continence and bal-
ance [17]. The extent of WML was rated by the Wahlund 
scale from MRI or CT scans at the time for diagnosis 
[18]. Lumbar puncture was performed preoperatively 
with the patient in recumbent position. In the improved 
group the median improvement was 26 points and in the 
non-improved group the median was 1 point (Table  2). 
All patients received a ventriculo-peritoneal shunt with 
a programmable valve with an anti-siphon device and a 
Rickham reservoir. All had working shunts and none had 
complications at the time for evaluation.
Twenty control subjects were chosen from a popula-
tion of volunteers who had given consent to CSF sam-
pling prior to knee surgery. The controls had no history 
of neurological or psychiatric disease, a normal clini-
cal neurological examination and a normal mini-mental 
state examination score. They consisted of eight men 
and 12 women aged 71.2 (±6.4). There was no difference 
in age between the three subcategories (controls, iNPH 
improved and iNPH non-improved).
CSF analyses
Amyloid β isoforms (Aβ38, Aβ40, and Aβ42) were 
analyzed by electrochemiluminescence assays (Meso 
Scale Discovery, Gaithersburg, MD, USA). The APLP1-
derived peptides APL1β25, APL1β27, and APL1β28 
were analyzed using a commercial ELISA (IBL Interna-
tional, Hamburg, Germany). The samples were analyzed 
according to the kit insert with minor modifications. 
The CSF samples were diluted 1:20 for APL1β25, 1:10 
for APL1β27, and 1:5 for APL1β28 by the dilution buffer 
contained in the kit. All samples were analyzed in dupli-
cate and the CV % for standards and samples was <5 %.
NFL was measured by ELISA technology using a com-
mercial kit (NF-Light, UmanDiagnostics, Umeå, Sweden) 
with a lower limit of detection of 50 ng/L. For astroglia 
activation, CSF YKL-40 concentration was measured by 
Table 1 Clinical characteristics of  iNPH patients at  base-
line
Improved Non-improved
n = 10 n = 10
Age (mean ± SD) 70.3 ± 3.2 71.6 ± 8.0 ns
Sex (male/female) 5/5 7/3 ns
Sickness duration (month) 42 ± 21 34 ± 28 ns
Diabetes (y/n) 2/8 2/8 ns
Hypertension (y/n) 5/5 6/4 ns
Cardiovascular disease (y/n) 2/8 1/9 ns
MMSE (median, IQ-range) 23 (22–28) 26 (24–28) ns
WML (median, IQ-range) 6 (4–10) 11 (5–20) ns
Evans index (median, IQ-range) 0.43 (0.38–0.46) 0.39 (0.36–0.41) ns
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solid phase sandwich ELISA (R&D Systems, Inc., Minne-
apolis, Minnesota, USA) according to the manufacturer’s 
instructions. All analyses were performed batch-wise on 
one occasion by board-certified laboratory technicians at 
the Clinical Neurochemistry Laboratory at Sahlgrenska 
University Hospital, Mölndal, Sweden. Intra-assay coef-
ficients of variation were below 10 %.
Statistics
Non-parametric methods were used for analyses. For 
comparisons between two groups the Mann–Whitney 
U test was performed and for comparisons between the 
three subgroups, the Kruskal–Wallis test was performed. 
For comparison of two proportions, Fisher’s exact test 
was used. For association between two independent vari-
ables, the Spearman rank order correlation was chosen. 
The level of significance chosen was p = 0.05, if not oth-
erwise stated. No correction for the mass-significance 
effect was made in order to avoid type II errors. Statisti-
cal analyses were made using IBM® SPSS® Statistics for 
Windows version 21.
Results
CSF concentrations of sAPPα, sAPPβ, Aβ38, Aβ40, Aβ42 
and APL1β28 were significantly lower and APL1β25 and 
27 significantly higher in iNPH patients compared to 
healthy controls. Levels of NFL and YKL 40 did not dif-
fer between iNPH patients and healthy controls (Table 3; 
Fig. 1). The APL1β28/total APL1β ratio and the Aβ42/to 
total Aβ ratio was lower in patients with iNPH in com-
parison with healthy controls (Fig. 2).
There were no differences in any of the CSF biomark-
ers between improved and non-improved iNPH patients 
(Table 4).
Discussion
Our data showing substantially reduced CSF concentra-
tions of Aβ38, Aβ40, Aβ42, sAPPα and sAPPβ in patients 
with iNPH, confirm earlier results [6–9, 11, 19–22]. In con-
trast, APLP1 in CSF was mildly but significantly, changed 
with an increase in APL1β25 and APL1β27 and a slight 
decrease of APL1β28, compared with controls. The ratios 
APL1β28/total APL1β and Aβ42/total Aβ were reduced in 
patients with iNPH. However, there were no differences in 
any CSF biomarker between improved and non-improved 
iNPH patients after treatment with shunt surgery.
This explorative study was in part designed to identify 
predictive alterations in the amyloid CSF pattern. We 
included two small groups representing iNPH patients 
that benefitted the most and those without any response 
to surgical treatment with shunting, in order to identify 
possible differences. However, we found no differences in 
CSF biomarkers between improved and non-improved 
patients. The low number of cases in each group may 
have been a limitation in this study. However, if there are 
subtle variances in CSF amyloid concentrations linked 
to responsiveness that could be identified in larger sam-
ple sets, we believe that these would be of minor clinical 
importance. Lumbar CSF as opposed to ventricular CSF 
was analysed to enhance the practical applicability of the 
generated results. Ventricular CSF might however pro-
vide a different pattern as it probably mirrors brain meta-
bolic processes more accurately.
The reduced CSF concentrations of Aβ38, Aβ40, Aβ42, 
sAPPα and sAPPβ in iNPH is consistent with earlier find-
ings [6, 7, 9, 11, 19–23], and compatible with a reduction 
in the concentrations of APP-derived proteins in the CSF 
of iNPH-patients. iNPH is a disorder of disturbed CSF 
dynamics and/or consequences thereof. Recent insights 
into the glymphatic system, has provided possibilities for 
a new route for clearance of excess fluid and interstitial 
metabolites, including Aβ, from the brain parenchyma 
[24, 25], together with clearance of Aβ across the blood–
brain barrier (BBB) via the LRP-1 receptor [26]. In the 
glymphatic system, there may be a para arterial influx of 
CSF from the subarachnoid space into the brain paren-
chyma where convective flow of interstitial fluid (ISF) 
helps to clear metabolic waste by para venous clearance 
towards the cervical lymph system, a system that seems 
to impair with aging [25, 27]. However, clear evidence 
Table 2 iNPH scale score pre op, post op and outcome (median and IQ-range)
Pre op Post op Outcome
Improved Non-improved Improved Non improved Improved Non-improved
n = 10 n = 10 n = 10 n = 10 n = 10 n = 10
Gait domain 33 (16–48) 54 (35–69) 84 (57–100) 50 (34–81) 49 (26 to 57) −1 (−6 to 11)
Cognitive domain 64 (37–73) 60 (46–80) 75 (57–85) 69 (48–80) 10 (6 to 21) 3 (−6 to 11)
Continence domain 60 (20–80) 80 (60–80) 90 (75–100) 70 (55–80) 30 (0 to 45) 0 (−20 to 5)
Balance domain 67 (67–71) 67 (67–83) 75 (67–87) 67 (67–83) 0 (−4 to 20) 0 (−16 to 0)
Total iNPH score 50 (36–64) 63 (56–70) 77.3 (71–87) 64 (52–71) 26 (21 to 30) 1 (−3 to 3)
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for this clearance is still lacking. In iNPH the CSF flow 
above the convexities is reduced and redirected into the 
ventricles and iNPH patients often present with a dispro-
portionately enlarged subarachnoid-space [28, 29]. These 
findings could hypothetically be in accordance with a dis-
turbance of CSF/ISF exchange as the dilated paravascular 
spaces could impair CSF/ISF exchange. Although specu-
lative, it could be hypothesized that the reduced con-
centrations of APP-derived proteins in the CSF of INPH 
patients could be due to stagnation of the flow in the 
periventricular ISF with reduced clearance of Aβ. This, 
however, remains to be proven. Regardless, levels of APP-
derived proteins in CSF are affected by both production 
and clearance of APP, and also by the ISF/CSF itself. This 
could make estimates of tissue levels in relation to CSF 
concentration problematic in patients with iNPH [30].
CSF APP-derived proteins increase after surgery, more 
in improved patients than in those that do not improve 
Table 3 Biomarker levels in  iNPH and  controls (median 
and IQ range)
Arrows indicating biomarker levels in iNPH in comparison with controls
ns non-significant
* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001
iNPH Controls
n = 20 n = 20
NFL (ng/L) 1185 (731–2103) 938 (610–2141)
APL1β25 (ng/L) 2591 (2296–2951) ↑ 2180 (1898–2386)***
APL1β27 (ng/L) 1083 (887–1177) ↑ 874 (796–964)***
APL1β28 (ng/L) 1423 (1317–1550) ↓ 1621 (1422–1797)**
Aβ38 (ng/L) 502 (266–625) ↓ 1114 (819–1445)***
Aβ40 (ng/L) 3676 (2190–4748) ↓ 7682 (6366–9809)***
Aβ42 (ng/L) 241 (144–405) ↓ 754 (493–1058)***
sAPPα (ng/mL) 207 (157–259) ↓ 416 (323–665)***
sAPPβ (ng/mL) 119 (92–170) ↓ 280 (182–389)***
YKL40 (ng/mL) 122 (90–167) 137 (104–177)
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Fig. 1 Scatter plot showing CSF concentrations of Amyloids (Aβ38, 40, 42), APLP1 derivates (APL1β25, 27, 28) and amyloid precursor proteins 
(sAPPα, β) in 20 patients with iNPH and 20 controls. Medians are indicated by horizontal lines. P values indicate the level of significance. The differ-
ences between the difference in concentrations of APLP1-derived proteins are, although statistically significant, more modest
Page 5 of 7Jeppsson et al. Fluids Barriers CNS  (2016) 13:13 
[6, 11]. Even if not designed to analyze such changes, the 
present study does not contradict these findings. The pre-
sumed reduction in CSF concentrations of the amyloid-
derived proteins could reflect a pathophysiological aspect 
of iNPH that is not directly linked with prediction. The 
irreversibility in non-improved iNPH patients could be due 
to either tissue damage related to iNPH or damage related 
to other factors such as co-morbidities e.g. cerebrovascular 
lesions, as there was a tendency of more profound WML in 
the non-improved group even if not reaching statistical sig-
nificance. However, cerebrovascular disease is not a nega-
tive predictor of outcome after shunt surgery [31].
Contrary to the profound alterations in APP metab-
olites, the APLP1-derived peptides showed only 
minor changes with a small elevation in APL1β25 and 
APL1β27 and a slight reduction of APL1β28. APP and 
APLP1 are processed by the same enzymes, including 
γ-secretase [10, 12, 13, 32], and the results could indi-
cate that the two substrates compete with each other 
at the active site of γ-secretase. If APP expression is 
reduced, as most data suggest it is in iNPH, there would 
be more γ-secretase available for the processing of 
APLP1. The processing occurs by γ-secretase cleaving 
at amino acid 28 of the membrane-spanning β-domain 
of APLP1 and then working its way towards the N-ter-
minus of the protein. Increased processing of APLP1 
by γ-secretase would thus result in decreased concen-
tration of APL1β and increased concentrations of the 
shorter forms [33, 34]. This is exactly what we observe 
in iNPH. Over-expression of APP results in a decrease 
of APL1β, which supports this substrate competition 
hypothesis [35].
There is a difference in APP-metabolite production pat-
tern between iNPH and AD. In iNPH there is a general 
suppression of APP-metabolites in CSF whereas in AD, 
there is an isolated Aβ42 reduction, whereas the other 
Aβ-isoforms are unaffected [36]. Moreover, the internal 
composition of Aβ production differs as shown in the 
APL1β28/total APL1β ratio. In our opinion, this provides 
further evidence against a common pathological etiology 
and might aid in the differential diagnosis of iNPH from 
AD by CSF biomarkers [37].
Conclusions
This data lends further support to a diagnostic profile in 
iNPH consisting of a general reduction in CSF concen-
tration of APP-derived proteins. That the amyloid-like 
proteins behave in a different pattern could support the 
specificity and importance of the APP-down-regulation 
in iNPH. The study indicates that the biomarker profile 
in iNPH is consistent between patients who improve 
by shunt insertion and those who do not; therefore, our 
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Fig. 2 The relative ratios of APL1β28 to total APL1β and Aβ42 to total Aβ in CSF in 20 patients with iNPH and 20 Controls. P values show the level of 
significance
Table 4 Levels of  biomarkers in  improved vs non-
improved iNPH patents (median and IQ-range)
ns non-significant
Improved Non-improved
n = 10 n = 10
NFL (ng/L) 1186 (869–1670) 1085 (699–2432) ns
APL1β25 (ng/L) 2532 (2174–2958) 2820 (2401–2954) ns
APL1β27 (ng/L) 1067 (900–1157) 1085 (867–1214)  ns
APL1β28 (ng/L) 1423 (1264–1568) 1458 (1291–1562) ns
Aβ38 (ng/L) 500 (308–605) 503 (224–677)  ns
Aβ40 (ng/L) 3731 (2642–4740) 3677 (1522–4789)  ns
Aβ42 (ng/L) 241 (155–370) 244 (122–438) ns
sAPPα (ng/mL) 205 (175–279) 212 (144–297) ns
sAPPβ (ng/mL) 114 (95–155) 127 (75–181) ns
YKL40 (ng/mL) 122 (99–153) 134 (84–180)  ns
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results do not lend support to the idea that these markers 
can be used for predictive purposes, but rather as an aid 
in the diagnosis of iNPH. Further studies will be needed 
to replicate the results and to expand the knowledge on 
the role of a possible altered amyloid metabolism for the 
pathogenesis of iNPH and the potential use of markers of 
amyloid metabolism to identify shunt responders needs 
to be further elucidated.
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